Welcome to our dedicated page for Envoy Medical SEC filings (Ticker: COCH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Envoy Medical's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Envoy Medical's regulatory disclosures and financial reporting.
Envoy Medical, Inc. is soliciting proxies for its 2026 Annual Meeting of Stockholders to be held on May [12], 2026 to consider director elections and six proposals.
Holders of record of Class A Common Stock as of March 13, 2026 may vote; 76,881,110 shares outstanding were entitled to vote. Key proposals include election of two Class III directors; ratification of Grant Thornton LLP as auditor; an advisory vote on named executive officer compensation; amendments to the 2023 Equity Incentive Plan to add 6,000,000 shares (increasing the plan to 10,000,000 shares, ~11.5% of issued and outstanding Class A); amendment to the ESPP to add 1,200,000 shares (increasing the ESPP to 1,500,000 shares); and shareholder approval under Nasdaq rules for the exercisability and issuance of up to 123,750,000 shares issuable upon warrants issued in the company’s February 12, 2026 offering (offering price $0.40 per share).
Envoy Medical, Inc. has regained compliance with the Nasdaq Capital Market’s continued listing standards. Nasdaq confirmed that the company now meets Listing Rule 5550(b)(2) after previously receiving a notice in February 2025 for not maintaining the required $35 million Market Value of Listed Securities.
The company attributes its renewed compliance to strategic financing initiatives that substantially strengthened its balance sheet and will remain under a one-year discretionary panel monitor starting February 12, 2026. Envoy Medical states it believes it has an achievable plan to stay in compliance and continue trading on Nasdaq under the symbol COCH.
Patel Mona Chetan reported open-market purchase transactions in a Form 4 filing for COCH. The filing lists transactions totaling 812,500 shares at a weighted average price of $0.40 per share. Following the reported transactions, holdings were 187,500 shares.
Potashnick Robert reported open-market purchase transactions in a Form 4 filing for COCH. The filing lists transactions totaling 552,500 shares at a weighted average price of $0.40 per share. Following the reported transactions, holdings were 127,500 shares.
Kantor Susan reported open-market purchase transactions in a Form 4 filing for COCH. The filing lists transactions totaling 249,990 shares at a weighted average price of $0.40 per share. Following the reported transactions, holdings were 57,690 shares.
BRYNELSEN CHARLES reported open-market purchase transactions in a Form 4 filing for COCH. The filing lists transactions totaling 2,600,000 shares at a weighted average price of $0.40 per share. Following the reported transactions, holdings were 600,000 shares.
Lucas Brent T. reported open-market purchase transactions in a Form 4 filing for COCH. The filing lists transactions totaling 162,500 shares at a weighted average price of $0.40 per share. Following the reported transactions, holdings were 37,500 shares.
TAYLOR GLEN A reported open-market purchase transactions in a Form 4 filing for COCH. The filing lists transactions totaling 48,750,000 shares at a weighted average price of $0.40 per share. Following the reported transactions, holdings were 11,250,000 shares.
Envoy Medical stockholder Glen A. Taylor filed an amended Schedule 13D to update his ownership after a February 2026 investment. He purchased 18,750,000 shares of Class A Common Stock together with Series A-1 Warrants for 11,250,000 shares and Series A-2 Warrants for 18,750,000 shares at a combined price of $0.40 per share and accompanying warrants, for an aggregate $7,500,000 funded with personal funds.
The common warrants have a $0.40 exercise price and become exercisable after stockholder approval of the warrant share issuance, with Series A-1 Warrants expiring up to 24 months after that approval (or earlier upon Milestone 1) and Series A-2 Warrants up to 60 months (or earlier upon Milestone 2). As of February 12, 2025, he is treated as beneficially owning 68,909,614 shares of Class A Common Stock, or 84.8% of the class, based on 76,881,110 shares outstanding immediately following the company’s offering, including the warrant shares. On the same date, he directly holds 29,040,049 outstanding shares, or 37.7% of those outstanding shares.